Novo Nordisk CEO Talks Weight Loss Drug Supply

Novo Nordisk is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples with supply constraints and competition from Eli Lilly & Co. CEO Lars Fruergaard Jorgensen says the company will continue to ramp up supply of its popular weight-loss drug "gradually." He spoke with Bloomberg's Katie Greifeld and Romaine Bostick. See omnystudio.com/listener for privacy information.